Associated Genetic Biomarkers
TACSTD2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains TACSTD2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with TACSTD2 status in the inclusion eligibility criteria most commonly target endometrial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is TACSTD2 Expression .
Sacituzumab govitecan is the most frequent therapy in trials with TACSTD2 as an inclusion criteria .
Significance of TACSTD2 in Diseases
Endometrial Carcinoma +
TACSTD2 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TACSTD2 status and endometrial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.